Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Cetuximab + MK-1084 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Cetuximab | Erbitux | IMC-C225 | EGFR Antibody 60 | Erbitux (cetuximab) is a monoclonal antibody directed against EGFR, which inhibits signal transduction and cell proliferation (PMID: 28695301). Erbitux (cetuximab) is FDA approved for use in head and neck squamous cell carcinoma and KRAS wild-type, EGFR positive colorectal cancer (FDA.gov). |
MK-1084 | MK 1084|MK1084 | KRAS G12C inhibitor 34 | MK-1084 is a selective inhibitor of KRAS G12C, which inhibits downstream signaling, potentially resulting in decreased tumor cell proliferation, and antitumor activity (NCI Drug Dictionary, Ann Oncol 34 (2023): S466-S467). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05067283 | Phase I | MK-1084 MK-1084 + Pembrolizumab Carboplatin + MK-1084 + Pembrolizumab + Pemetrexed Disodium Cetuximab + MK-1084 Cetuximab + Fluorouracil + Leucovorin + MK-1084 + Oxaliplatin | A Study of MK-1084 in KRAS Mutant Advanced Solid Tumors (MK-1084-001) | Recruiting | USA | TUR | POL | NZL | ITA | ISR | ESP | DNK | CHE | CAN | AUS | 7 |